J Thorac Oncol: RNA deep sequencing shows that fusion heterogeneity can predict the therapeutic effect of crizotinib on ALK rearranged non-small cell lung cancer

ALK rearrangement of non-small cell lung cancer ( NSCLC ) gene fusion variants may predict the prognosis of patients, but the results of previous studies are still uncertain
.

The coexistence of fusion isoforms in the same tumor may affect the efficacy of targeted therapy, but relevant studies have not been conducted yet

ALK rearrangement of non-small cell lung cancer ( NSCLC ) gene fusion variants may predict the prognosis of patients, but the results of previous studies are still uncertain

The study included 51 Ming non-small cell lung cancer patients met the inclusion criteria, follow-up to 2020 Nian 12 Yue 31 Ri
.

Including 33 women (65.

The study included 51 Ming non-small cell lung cancer patients met the inclusion criteria, follow-up to 2020 Nian 12 Yue 31 Ri

Use single-tube RNA and DNA sequencing methods to detect EML4-ALK variant types

There was no statistically significant difference in PFS between patients with v3 tumors and patients with non-v3 tumors (median PFS: 8.

PFS

 PFS

Cox regression analysis showed that compared with v3 and non-v3 tumor patients, PFS was in the univariate model (HR [95% CI]: 1.
72 [0.
93-3.
18]) and the multivariate model (HR [95% CI]: 1.
05 [0.
45 2.
43] ) Are not statistically different
.

Compared with patients with single subtypes, the PFS of the multiple subtypes group was worse, and the difference was statistically significant in the univariate model (HR [95% CI]: 2.

Cox regression analysis showed that compared with v3 and non-v3 tumor patients, PFS was in the univariate model (HR [95% CI]: 1.

Analysis of related factors of PFS and OS

Analysis of related factors of PFS and OS

The survival time (OS) of v3 patients was shorter than that of non-v3 patients, but the difference was not statistically significant (median survival time: 21.
6 m vs 38.
5 m, P = 0.
149)
.

The OS of patients with multiple subtypes was shorter than that of patients with single subtype tumors (median OS: 18.

The survival time (OS) of v3 patients was shorter than that of non-v3 patients, but the difference was not statistically significant (median survival time: 21.

                      OS

OS

In univariate Cox regression, the only baseline clinical feature related to OS was age (HR [95% CI]: 1.
04 [1.
01-1.
07]; OS in patients with v3 tumors was compared with non-v3 patients before adjustment (HR [95 % CI]: 1.
73[0.
82-3.
65]) and after adjusting for potential confounding factors (HR [95% CI]: 1.
06[0.
39-2.
87]), there was no statistical difference
.

At the same time, before and after adjusting for potential confounding factors, there was no statistical difference .

In univariate Cox regression, the only baseline clinical feature related to OS was age (HR [95% CI]: 1.
04 [1.
01-1.
07]; OS in patients with v3 tumors was compared with non-v3 patients before adjustment (HR [95 % CI]: 1.
73[0.
82-3.
65]) and after adjusting for potential confounding factors (HR [95% CI]: 1.
06[0.
39-2.
87]), there was no statistical difference
.
At the same time, before and after adjusting for potential confounding factors, there was no statistical difference .
Compared with single subtypes, patients with multiple subtypes are associated with a higher risk of death (HR [95% CI]: 2.
46 [1.
16-5.
22] and 3.
74 [1.
26 11.
13])
.
In the stratified analysis, the fusion variant type is associated with OS Irrelevant (HR [95% CI]: univariate 0.
57[0.
21-1.
53], multivariate 0.
67[0.
21-2.
16])
.
In the non-v3 group, multiple subtypes are associated with a higher risk of death compared with single subtypes Correlation (after adjusting for potential confounding factors, univariate model HR=4.
24, [95% CI] [1.
52-11.
80]), and multivariate model HR=12.
56, [95% CI]: [2.
87-54.
98])
.

In summary, studies have shown that intratumoral EML4-ALK subtypes can predict the efficacy of targeted therapy in patients with ALK rearrangement in non-small cell lung cancer (NSCLC)
.

In summary, studies have shown that intratumoral EML4-ALK subtypes can predict the efficacy of targeted therapy in patients with ALK rearrangement in non-small cell lung cancer (NSCLC)
.
In summary, studies have shown that intratumoral studies have shown that intratumoral studies have shown that intratumoral EML4-ALK subtypes can predict the efficacy of targeted therapy in patients with ALK rearrangement non-small cell lung cancer (NSCLC)
.
EML4-ALK subtype can predict the efficacy of targeted therapy in patients with ALK rearrangement non-small cell lung cancer (NSCLC)
.

Original source:

Original source:

Song Z, Lian S, Mak S, Chow MZ, Xu C, Wang W, Keung HY, Lu C, Kebede FT, Gao Y, Cheuk W, Cho WCS, Yang M, Zheng Z.
Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
J Thorac Oncol.
2021 Oct 6:S1556-0864(21)03219-6.
doi: 10.
1016/j.
jtho.
2021.
09.
016.
Epub ahead of print.
PMID: 34626839.

Song Z, Lian S, Mak S, Chow MZ, Xu C, Wang W, Keung HY, Lu C, Kebede FT, Gao Y, Cheuk W, Cho WCS, Yang M, Zheng Z.
Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
J Thorac Oncol.
2021 Oct 6:S1556-0864(21)03219-6.
doi: 10.
1016/j.
jtho.
2021.
09.
016.
Epub ahead of print.
PMID: 34626839.
Leave a message here